ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)
- 1 June 2018
- journal article
- review article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 24, S95-S107
Abstract
No abstract availableKeywords
This publication has 121 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML PatientsThe Journal of Infectious Diseases, 2011
- Pathogenesis of Progressive Multifocal Leukoencephalopathy—RevisitedThe Journal of Infectious Diseases, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Treatment with a sphingosine analog does not alter the outcome of a persistent virus infectionVirology, 2010
- Asymptomatic Reactivation of JC Virus in Patients Treated with NatalizumabNew England Journal of Medicine, 2009
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple MyelomaNew England Journal of Medicine, 2008
- S1P1 Receptor Signaling Overrides Retention Mediated by Gαi-Coupled Receptors to Promote T Cell EgressImmunity, 2008
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005